Statement Of Changes In Equity [Abstract]

GenSight Biologics S.A. - Filing #2810901

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	—	—	30,702,000 EUR	197,051,000 EUR	26,220,000 EUR	—	—	190,937,000 EUR	—	1,633,000 EUR	15,279,000 EUR	—	170,024,000 EUR	—	27,625,000 EUR	—	181,211,000 EUR	1,158,000 EUR	—	—	28,617,000 EUR	15,989,000 EUR	137,726,000 EUR	181,175,000 EUR	1,158,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	26,220,000 EUR	26,220,000 EUR	—	—	—	— EUR	— EUR	—	— EUR	—	—	— EUR	—	27,625,000 EUR	—	— EUR	—	—	27,625,000 EUR	— EUR	—	—	—	—	—
Comprehensive income	26,111,000 EUR	26,220,000 EUR	—	—	—	109,000 EUR	0 EUR	—	0 EUR	—	—	0 EUR	—	27,748,000 EUR	—	124,000 EUR	—	—	27,625,000 EUR	0 EUR	—	—	—	—	—
Issue of equity	10,842,000 EUR	— EUR	—	—	—	— EUR	10,368,000 EUR	—	474,000 EUR	—	—	1,000 EUR	—	0 EUR	—	— EUR	—	—	— EUR	1,000 EUR	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	587,000 EUR	— EUR	—	—	—	587,000 EUR	— EUR	—	— EUR	—	—	— EUR	—	3,364,000 EUR	—	3,364,000 EUR	—	—	— EUR	— EUR	—	—	—	—	—